Cagrilintide cut weight up to 10.8% alone and 20.4% with semaglutide

How does cagrilintide work?

Cagrilintide is a fatty-acid-acylated analog of amylin, engineered for once-weekly dosing, that acts as a non-selective agonist at both amylin receptors (AMYR) and calcitonin receptors (CTR). Amylin is a pancreatic hormone co-secreted with insulin. It signals satiety and slows gastric emptying through amylin receptors.

The calcitonin receptor activity is a second signal entirely. It carries its own theoretical long-term questions that have nothing to do with GLP-1 pharmacology.

How is cagrilintide different from GLP-1 drugs?

Cagrilintide works through amylin receptors, a GPCR system distinct from the GLP-1 receptor that semaglutide and liraglutide target. Forums and vendor blogs often describe amylin and GLP-1 agonism as interchangeable "satiety mechanisms," and they are not.

GLP-1 receptor agonism drives its effects heavily through incretin signaling, insulinotropic action and glucagon suppression. Amylin receptor agonism works more through central nervous system satiety centers and gastric emptying delay, with less direct effect on insulin secretion.

Because the two systems are mechanistically distinct, combining cagrilintide with a GLP-1 agonist for an additive, not duplicative, effect is biologically plausible on first principles. Plausible mechanism and demonstrated clinical synergy are different claims, and only trials can show the second.

How much weight does cagrilintide alone produce?

Cagrilintide alone produced 6.0% to 10.8% weight loss over 26 weeks versus 3.0% on placebo in a dose-finding phase 2 trial (p<0.001 across doses) ^[1]. Doses ranged from 0.3 mg to 4.5 mg, and the top dose beat liraglutide 3.0 mg (10.8% versus 9.0%, p=0.03) ^[1]. GI safety was described as acceptable ^[1].

The phase 2 trial remains the largest standalone cagrilintide dataset. It shows a dose-dependent efficacy signal for cagrilintide on its own, not only as an add-on.

REDEFINE 1, a phase 3 trial far larger than the 2021 phase 2 trial, included a cagrilintide-only arm (n=302) that confirms single-agent efficacy ^[4]. The REDEFINE 1 abstract does not break out the monotherapy arm's own weight-loss figure.

Does cagrilintide plus semaglutide beat either drug alone?

Yes, in a 92-person phase 2 trial in type 2 diabetes: CagriSema produced 15.6% weight loss at 32 weeks, versus 8.1% for cagrilintide alone and 5.1% for semaglutide alone ^[3]. In that trial, 71% of combination participants lost more than 10% of bodyweight ^[3].

The trial is the strongest direct evidence for an additive rather than redundant effect. Its sample size is modest, and its population, people with type 2 diabetes, is specific.

An earlier 96-person phase 1b trial tested cagrilintide stacked with semaglutide 2.4 mg across ascending dose cohorts. It found no pharmacokinetic interaction between the two drugs and acceptable tolerability, and exploratory weight loss reached 15.4% at the top dose ^[2]. That trial was a safety and pharmacokinetic study, not an efficacy trial, so the 15.4% figure is hypothesis-generating, not confirmatory.

What did the REDEFINE 1 and REDEFINE 2 trials find?

REDEFINE 1 found that CagriSema produced 20.4% mean weight loss over 68 weeks versus 3.0% with placebo, a difference of 17.3 percentage points (p<0.001) ^[4]. REDEFINE 1 was larger and more recent than the phase 2 trials, with 3,417 participants from a general overweight and obesity population ^[4].

REDEFINE 2 enrolled 1,206 people with type 2 diabetes and found 13.7% weight loss with CagriSema versus 3.4% with placebo over 68 weeks ^[5]. In REDEFINE 2, 73.5% of combination participants reached an HbA1c of 6.5% or below, versus 15.9% on placebo ^[5]. The combination's effect extends to glycemic outcomes in a diabetic population, alongside weight loss.

The REDEFINE trials are registrational studies for the combination product, not for cagrilintide alone. Semaglutide's own trial record is laid out in semaglutide's evidence from three randomized trials.

How strong is the cagrilintide evidence?

Cagrilintide's evidence earns a B grade: five completed randomized trials, including two phase 3 trials, make it a strong evidence base by peptide standards. Molecules with only animal data or a single small human trial get lower grades.

Every one of the five trials is sponsor-funded by Novo Nordisk, the developer of both cagrilintide and semaglutide. No independent, non-sponsor-funded replication exists.

As of mid-2026, no regulatory agency has approved cagrilintide as a standalone product. The five completed randomized trials do not establish safety beyond their observed follow-up.

Does cagrilintide preserve lean mass?

No trial has shown it: none of the five cagrilintide trials reports DEXA scans, bioelectrical impedance or any other breakdown of fat versus lean mass loss. Their published endpoints are total bodyweight percentage change.

The idea that amylin agonism spares lean mass better than GLP-1 agonism is common in forum discussion. It usually traces back to older research on pramlintide, a short-acting amylin analog, or to general amylin physiology. Pramlintide's own weight-loss record covers that older drug.

Until a trial measures composition, "preserves lean mass" is a mechanistic hypothesis extrapolated from a related molecule, not a cagrilintide-specific finding. The same lean mass question for GLP-1 drugs is covered in GLP-1 muscle loss claims.

What are cagrilintide's dosing and side effects?

Cagrilintide is dosed once weekly by subcutaneous injection, with doses studied from 0.3 mg up to 4.5 mg in monotherapy and 2.4 mg in the CagriSema combination ^[1]⁠^[3]⁠^[4]⁠^[5]. Reported side effects cluster around gastrointestinal symptoms and injection-site reactions.

Nausea is generally described as dose-dependent. Anecdotal forum reports call it milder than with strong GLP-1 agonists, but the trials do not formally quantify that comparison.

When cagrilintide is stacked with a GLP-1 agonist, appetite suppression can compound to the point of inadequate caloric or nutrient intake. That is a practical risk, not a trial-documented adverse event in these trials.

The calcitonin receptor component raises a theoretical long-term signal worth tracking, because calcitonin receptor activation has drawn scrutiny in other drug classes. None of the five trials reports medullary thyroid or calcitonin-related adverse findings.

Sourcing matters separately from pharmacology. Any cagrilintide obtained outside a monitored trial or regulated pharmacy carries sterility, identity and purity risk with no quality assurance behind it.

What is still unknown about cagrilintide?

Four questions remain open:

• Stopping. None of the five trials addresses discontinuation, so whether weight regain, appetite rebound or tolerance shifts occur after stopping cagrilintide is not established.
• Long-term safety. The completed trials do not establish safety beyond their observed follow-up.
• Monotherapy dosing. None of the five trials is a dedicated, large phase 3 monotherapy trial setting the optimal dose of cagrilintide alone in the general overweight and obesity population.
• Body composition. Body composition outcomes specific to cagrilintide remain unstudied.

Anyone deciding whether to combine cagrilintide with a GLP-1 agonist should weigh a real additive signal in small-to-midsize trials against the absence of independent, non-sponsor-funded replication and of long-term outcome data beyond the 68-week trials.